The present invention relates to an autophagic cell targeted peptide and its use. More particularly, the present invention relates to a polypeptide comprising an amino acid sequence represented by the general formula (I) and specifically binding to an autophagic cell and a composition for detecting autophagic cells comprising the same as an active ingredient, a drug delivery composition containing the same as an active ingredient, and a composition for imaging comprising the same as an active ingredient. The peptide of the present invention specifically binds to the cell membrane of autophagic cells and can be applied to various kinds of tissues and cells. Also the detection and imaging effect of autophagy is remarkable in vitro and in vivo.

The present invention relates to an autophagic cell targeted peptide and its use. More particularly, the present invention relates to a polypeptide comprising an amino acid sequence represented by the general formula (I) and specifically binding to an autophagic cell and a composition for detecting autophagic cells comprising the same as an active ingredient, a drug delivery composition containing the same as an active ingredient, and a composition for imaging comprising the same as an active ingredient. The peptide of the present invention specifically binds to the cell membrane of autophagic cells and can be applied to various kinds of tissues and cells. Also the detection and imaging effect of autophagy is remarkable in vitro and in vivo.

In some embodiments, the present invention provides a recombinant protein comprising an affinity tag configured to attach the recombinant protein to a silicate surface, fused to a hydrogen sulfide scavenging enzyme.

In some embodiments, the present invention provides a recombinant protein comprising an affinity tag configured to attach the recombinant protein to a silicate surface, fused to a hydrogen sulfide scavenging enzyme.

One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.

One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

This present invention provides a novel peptide for inhibiting growth of microorganisms, a pharmaceutical composition, an antimicrobial composition comprising such novel peptide, and a method for inhibiting growth of microorganisms. The novel peptide for inhibiting growth of microorganisms has amino acid sequence: KX.sub.1LRX.sub.2X.sub.3X4RRWX.sub.5, wherein X.sub.1, X.sub.2, and X.sub.5 are selected from the group of W and R, respectively; X.sub.3 is selected from the group of V and P; and X.sub.4 is selected from the group of R and methylated W. The method for inhibiting growth of microorganisms disclosed in this present invention comprises administering the novel peptide, the pharmaceutical composition, or the antimicrobial composition.

This present invention provides a novel peptide for inhibiting growth of microorganisms, a pharmaceutical composition, an antimicrobial composition comprising such novel peptide, and a method for inhibiting growth of microorganisms. The novel peptide for inhibiting growth of microorganisms has amino acid sequence: KX.sub.1LRX.sub.2X.sub.3X4RRWX.sub.5, wherein X.sub.1, X.sub.2, and X.sub.5 are selected from the group of W and R, respectively; X.sub.3 is selected from the group of V and P; and X.sub.4 is selected from the group of R and methylated W. The method for inhibiting growth of microorganisms disclosed in this present invention comprises administering the novel peptide, the pharmaceutical composition, or the antimicrobial composition.

Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.